Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nortran Pharmaceutical -NRT.V -- Ignore unavailable to you. Want to Upgrade?

To: Wisee who wrote (647)	5/11/1998 2:48:00 AM
From: the truth	Read Replies (1) \| Respond to of 1185

Let's forget what happened a year ago and focus on the future. The real point is the approach that Nortran is taking with the science. The drugs target the damaged, not healthy tissue. The non-narcotic painkillers are a class of their own. So instead of debating on the stock jump up and down like a yo-yo, one must ask if they are comfortable with the company's approach. I think Hoffman-Laroche has answered that question for many of us. Two thumbs up for this deal for a company literally in the infancy of development. Set a price where you would buy this stock, and sit on it. What is the risk to reward? Definitely better when it was 0.80 then 3.00.